The main objective within the BACCHUS project involves setting in place best practice guidelines for reviewing EFSA’s (European Food Safety Authority) approach to health claims and establishing solid guidelines for the project partners which consists of 26 EU partners, including Creme Global. The health claim focus for this project concentrates on the effect of polyphenols and bioactive peptides on cardiovascular health.

Within the relevant work packages of BACCHUS, the project partners are conducting high quality research to look at different areas that need to be addressed to align with the health claim evaluation progress.

Accurate analytical methods have been developed, in order to quantify bioactive peptides and polyphenols in foods and food extracts, and to carry out product and bioactive characterisation. A bioavailability platform is set in place to understand the metabolism and absorption of specific compounds, while in another work package the mechanisms of action are being characterized using various in vitro and in vivo studies. This includes the assessment of human biomarkers of selected polyphenols and bioactive peptides. This information is fed into 7 randomized controlled human trials in order to evaluate, established biomarkers, the evidence of health benefits from bioactive peptides and polyphenol enriched foods. Furthermore, the effective dose required for those beneficial physiological effects will be estimated.

In order to establish if this effective dose can be achieved in a balanced diet, information is needed to feed into the health claim application dossier. This is where Creme Global’s expertise and unique model (Creme Nutrition®) is used to assess bioactive compound intakes in the population. Information on the content of bioactive peptides and polyphenols in foods is added to the eBasis platform and then applied to the Creme Nutrition® model to determine realistic distributions of intakes in European populations. Creme Global has been working on matching this bioactive data to the foods consumed in four European countries; Spain, Norway, Ireland and the UK, to assess accurate distributions of intakes of those compounds.

This research is examining robust and exploitable scientific evidence to support health claims, and to determine the cause and effect relationship between intakes and beneficial health impacts on cardiovascular health.